6/3 Post Exposure Prophylaxis study (treated after exposure to the virus)
et al., NEJM, June 3 2020, doi:10.1056/NEJMoa2016638 (Peer Reviewed)
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
COVID-19 cases are reduced by [49%, 29%, 16%] respectively when taken within ~[70, 94, 118] hours of exposure (including shipping delay). The treatment delay-response relationship is significant at p=0.002. PEP delayed treatment RCT.For more detailed analysis, see [1].6 independent analyses of the data in this study confirm efficacy: [2, 3, 4, 5, 6, 7, 8].Regarding the use of folic acid, see [9].
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Boulware et al., 6/3/2020, Randomized Controlled Trial, USA, North America, peer-reviewed, 24 authors.
risk of COVID-19 case, 17.0% lower, RR 0.83, p = 0.35, treatment 49 of 414 (11.8%), control 58 of 407 (14.3%).
risk of COVID-19 case, 25.1% lower, RR 0.75, p = 0.22, treatment 32 of 414 (7.7%), control 42 of 407 (10.3%), probable COVID-19 cases.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
